Company intelligence / Profile preview

Amalus Therapeutics

Ghent, East Flanders, Belgiumamalustherapeutics.com ↗

Ownership: Private
Employees: ~10
Development stage: Preclinical

Overview

Amalus Therapeutics has developed molecules that selectively target disease-associated fibroblasts while sparing normal ones. In animal models, their agents have normalized tumor environments, inhibited metastases, activated the immune system, and shown good tolerability. The approach aims to improve outcomes for cancer and fibrosis patients and can potentially enhance standard therapies. Clinical trials have not yet started.

Therapeutic areas: OncologyRare Diseases
Modalities: Small molecules (selective fibroblast modulators)
Industry: Biotech

Partnerships

BioInnovation Institute (BII), supported by Novo Nordisk Foundation—provides funding, lab access, network support.

Beyond the preview

Go deeper on Amalus Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Amalus Therapeutics.

Explore the full profile